You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 581 Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
581 Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023260025
Dec 2023105019
Jan 2024114013
Feb 2024126011
Mar 2024102012
Apr 20248207
May 20248009
Jun 20247507
Jul 20249809
Aug 202410409
Sep 202411505
Oct 2024140017
Nov 202412609
Dec 202486013
Jan 2025128012
Feb 202527013
Mar 20250012
Apr 2025004
May 20250010
Jun 2025008
Total17680224